Oncolytic virotherapy represents a promising approach for glioma therapy with challenges remain. Here, the authors show that IDH1-mutant gliomas exhibit increased susceptibility to oncolytic HSV-1 therapy due to impaired antiviral signaling, and that combining virotherapy with TIGIT blockade enhances antitumor immune responses and therapeutic efficacy.